Stocktoria
Medpace Holdings, Inc. MEDP
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 2016-08-11
Medpace Holdings, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.5B | $2.1B | $1.9B | $1.5B | $1.1B |
| SG&A expense | $197.6M | $180.2M | $161.4M | $131.4M | $108.4M |
| Operating income | $534.9M | $446.9M | $336.8M | $278.7M | $198.6M |
| Income tax | $91.3M | $71.5M | $52.9M | $37.5M | $20.0M |
| Net income | $451.1M | $404.4M | $282.8M | $245.4M | $181.8M |
| EPS (diluted) | $15.28 | $12.63 | $8.88 | $7.28 | $4.81 |
| Operating cash flow | $713.2M | $608.8M | $433.4M | $388.1M | $263.3M |
| Free cash flow | $681.9M | $572.3M | $396.7M | $351.2M | $235.1M |
| Cash & equivalents | $497.0M | $669.4M | $245.4M | $28.3M | $461.3M |
| Total assets | $2.0B | $2.1B | $1.7B | $1.4B | $1.7B |
| Total liabilities | $1.5B | $1.3B | $1.1B | $966.1M | $707.0M |
| Shareholders' equity | $459.1M | $825.5M | $559.0M | $386.4M | $952.9M |
Source: SEC EDGAR filings · CIK 0001668397 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.